Laboratory Diagnosis and Immunologic Characterization of Heritable Immune Disorde
Laboratory Diagnosis and Immunologic Characterization of Heritable Immune Disorde
批准号:
7613790
负责人:
Alexandra H Filipovich
金额:
$0.3万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-11-01 至 2009-10-31
关键词:
AdultAffectAmericanArtsCanadaCategoriesCell TransplantationChildClinicalClinical MedicineConsensusDevelopmentDiagnosisDiagnosticDiseaseElectronicsEuropeFacultyFundingGenetic screening methodHealthcare SystemsHematopoieticImmuneImmune System DiseasesImmunologic Deficiency SyndromesImmunologicsIndividualJournalsKnowledgeLaboratoriesLaboratory DiagnosisLaboratory ScientistsLatin AmericaNatural HistoryNorth AmericaOutcomePan GenusParticipantPatientsPeer ReviewPreparationPublishingResource SharingResourcesScientistSenior ScientistSourceTestingTravelVideotapebasecostcost effectiveimprovedinterestmembernext generationsymposiumtoolworking group
中文摘要
描述(申请人提供):遗传性免疫疾病的实验室诊断和免疫学特征-泛美共识会议:共享资源,共享知识这是一个为期两天的互动会议,将于2008年11月8日和9日举行。在诊断和治疗遗传性免疫缺陷(通常被称为原发性免疫缺陷疾病,简称PIDD)方面具有优势的主要学术中心将出席会议。如果资金允许,将从每个北美中心邀请至少两名个人:例如一名资深科学家和一名初级教员,或一名临床医生和一名实验室科学家:例如一名“专家”和一名下一代“专家”。将邀请所有学术参与者,包括工作组成员、主持人和演讲者,并提供他们的旅费。大多数参与者将来自美国和加拿大,如果非NIH来源的资金允许,还有少数受邀者来自拉丁美洲和欧洲。一些代表美国相关企业组织的科学家可能会自费参加。将讨论的主题包括:1)概述北美可用于PIDD的临床实验室测试,包括基因测试;2)审查现有的和新出现的PIDD明确诊断的快速和具有成本效益的战略;3)确定新的和新兴的诊断工具,以及如何将其应用于临床医学;4)为准确诊断和管理不同类别的PIDD开发范例;5)优化(现有的)对PIDD感兴趣的专业人员网络。将对包括讨论在内的会议记录进行录像,以协助编写协商一致的文件。我们计划在同行评议的期刊上发表这些文章,并为此发起了讨论。此外,如果可行和负担得起,将开发和定期管理北美诊断PIDD资源的电子简编,可能会在泛美免疫缺陷组织(PAGID)的主持下进行。100多种原发免疫缺陷疾病虽然个别罕见,但由于管理患有这种疾病的儿童和成人的复杂性和成本,作为一个群体,它们对卫生保健系统构成了重大负担。同样明显的是,有许多人受到所谓新出现的PIDD的影响,但尚未广泛获得强有力的诊断工具,而且对其自然历史了解甚少。大多数PIDD是过早致死的,相当数量的PIDD只能通过造血细胞移植来“治愈”。由于所有治疗的更好结果取决于早期和正确的诊断,因此获得最先进的实验室工具和对结果的最佳“专家”解释对于改善PIDD患者的结果至关重要。
英文摘要
DESCRIPTION (provided by applicant): Laboratory Diagnosis and Immunologic Characterization of Heritable Immune Disorders - a Pan American Consensus Conference: Sharing Resources, Sharing Knowledge This is planned as a 2 day interactive conference to be held November 8 and 9, 2008. Major academic centers with strengths in diagnosis and treatment of heritable immunodeficiencies (often termed Primary Immunodeficiency Disorders, or PIDDs) will be represented. If funding permits, at least two individuals from each North American center will be invited: e.g. a senior scientist and a junior faculty member, or a clinician and a laboratory scientist: e.g. an "expert" and a next generation "expert". All academic participants including members of working groups, moderators and speakers will be invited and their travel expenses will be provided. The majority of participants will be from U.S. and Canada, with a handful of invitees from Latin America and Europe if funding from non-NIH sources permits. A few scientists representing relevant corporate organizations in the U.S. may attend at their own expense. Topics to be discussed will cover : 1) an overview of clinical laboratory based testing, including genetic testing, available in North America for PIDDs, 2) review of existing and emerging rapid and cost effective strategies for definitive diagnosis of PIDDs, 3) identification of new and emerging diagnostic tools and how to move them into clinical medicine 4) development of paradigms for accurate diagnosis and management of different categories of PIDDs, 5) optimization of (existing) networks of professionals with an interest in PIDDs. Conference proceedings, including discussion, will be videotaped to assist preparation of consensus documents. We plan to publish these in peer-reviewed journals, and have initiated discussions to that end. Furthermore, if practical and affordable, an electronic compendium of resources for diagnosis of PIDD in North America, will be developed and regularly curated, perhaps under the auspices of PAGID (Pan American Group for Immunodeficiencies). The more than 100 primary immunodeficiency disorders (PIDDs), while individually rare, as a group represent a significant burden on the health care system due to the complexity and cost of managing children and adults with such disorders. It is also clear that there are many individuals affected by so-called emerging PIDDs for which robust diagnostic tools are not yet widely available, and the natural history is poorly understood. Most of the PIDDs are prematurely lethal and a significant number can only be "cured" by hematopoietic cell transplantation. Since better outcomes with all treatments hinge on early and correct diagnoses, access to state of the art laboratory tools and the best "expert" interpretation of results is central to improving outcomes for patients with PIDDs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Histiocyte Society Annual Meeting to be Held in Boston
-
批准号:8062830
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2011
-
负责人:Alexandra H Filipovich
-
依托单位:
Survival and Disease Correction Following Hematopoietic Cell Transplantation of W
-
批准号:8326284
-
项目类别:
-
资助金额:$16.42万
-
财政年份:2009
-
负责人:Alexandra H Filipovich
-
依托单位:
CONFERENCE ON THE ROLE OF IMMUNODEFICIENCY IN CANCER
-
批准号:3433826
-
项目类别:
-
资助金额:$0.6万
-
财政年份:1986
-
负责人:Alexandra H Filipovich
-
依托单位:
UTILIZATION OF THE IMMUNODEFICIENCY CANCER RESEARCH
-
批准号:3548913
-
项目类别:
-
资助金额:$8.76万
-
财政年份:1986
-
负责人:Alexandra H Filipovich
-
依托单位:
UTILIZATION OF THE IMMUNODEFICIENCY CANCER RESEARCH
-
批准号:3548912
-
项目类别:
-
资助金额:$9.53万
-
财政年份:1986
-
负责人:Alexandra H Filipovich
-
依托单位:
UTILIZATION OF THE IMMUNODEFICIENCY CANCER REGISTRY
-
批准号:2305029
-
项目类别:
-
资助金额:$5.56万
-
财政年份:1983
-
负责人:Alexandra H Filipovich
-
依托单位:
UTILIZATION OF THE IMMUNODEFICIENCY CANCER REGISTRY
-
批准号:2305030
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1983
-
负责人:Alexandra H Filipovich
-
依托单位:
Survival and Disease Correction Following Hematopoietic Cell Transplantation of W
-
批准号:8382481
-
项目类别:
-
资助金额:$3.73万
-
财政年份:--
-
负责人:Alexandra H Filipovich
-
依托单位:
Survival and Disease Correction Following Hematopoietic Cell Transplantation of W
-
批准号:8522132
-
项目类别:
-
资助金额:$5.41万
-
财政年份:--
-
负责人:Alexandra H Filipovich
-
依托单位:
海外基金